Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting session on the front-line management of ALK-positive Lung Cancer.
The frontline management of ALK+ NSCLC has undergone a paradigm shift over the last decade, with the introduction of targeted therapies. The discovery of the EML4 fusion gene and the subsequent development of crizotinib in 2011 have significantly improved personalized medicine for ALK-mutated non-small cell lung cancer. The recent data from the CROWN trial further supports the use of lorlatinib as a first-line treatment option for ALK+ NSCLC, with a significant improvement in progression-free survival compared to other ALK inhibitors.
The CROWN trial demonstrated that lorlatinib has a higher intracranial response rate and better CNS progression-free survival than other ALK inhibitors. This suggests that lorlatinib is particularly effective in managing brain metastases, common in ALK+ NSCLC. These findings highlight the importance of considering lorlatinib as the first-line treatment option for ALK+ NSCLC patients with brain metastases.
Therefore, get an overall knowledge regarding the management of ALK+ NSCLC. Listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
2.
Severe obesity associated with reduced prevalence of recommended cancer screenings
3.
Dual imaging capsule captures 3D tissue and blood vessel changes for early esophageal cancer diagnosis
4.
Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.
5.
Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer
1.
Clinical Frameworks in Hematology for Better Care
2.
The Latest Research on Wiskott Aldrich Syndrome
3.
Exposure-Response in Immuno-Oncology: Mechanisms, Clinical Insights, and Practical Implications
4.
Preventing Sarcopenia During Cancer Treatment
5.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
2.
Clinical Insights in Oncology
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation